European Union - English - EMA (European Medicines Agency)

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirals for systemic use - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.

Singapore - English - HSA (Health Sciences Authority)

star medical co pte ltd - general hospital - a device used to measure and indicate the rate of flow of a gas passing through it.

Singapore - English - HSA (Health Sciences Authority)

roche diagnostics asia pacific pte ltd - clinical chemistry - in vitro test for the quantitative determination of creatinine in human serum, plasma and urine on the cobas c 111 system.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

redox limited - aluminium phosphide - tablet (inc. pellet, bolus, suppository, capsule) - aluminium phosphide mineral-aluminium active 560.0 g/kg - mixed function pesticide - stored barley seed | stored breakfast cereal | stored bulk stock feed | stored cereal grain | stored cereal produce | stored coc - stored commodity pests

European Union - English - EMA (European Medicines Agency)

gilead sciences ireland uc - tenofovir disoproxil fumarate - hepatitis b, chronic; hiv infections - antivirals for systemic use - hiv 1 infectionviread 123 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of hiv 1 infected paediatric patients, with nrti resistance or toxicities precluding the use of first line agents, aged 6 to < 12 years who weigh from 17 kg to less than 22 kg.the choice of viread to treat antiretroviral experienced patients with hiv 1 infection should be based on individual viral resistance testing and/or treatment history of patients.hepatitis b infectionviread 123 mg film coated tablets are indicated for the treatment of chronic hepatitis b in paediatric patients aged 6 to < 12 years who weigh from 17 kg to less than 22 kg, withcompensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum alt levels, or histological evidence of moderate to severe inflammation and/or fibrosis.  with respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.hiv 1 infectionviread 163 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of hiv 1 infected paediatric patients, with nrti resistance or toxicities precluding the use of first line agents, aged 6 to < 12 years who weigh from 22 kg to less than 28 kg.the choice of viread to treat antiretroviral experienced patients with hiv 1 infection should be based on individual viral resistance testing and/or treatment history of patients.hepatitis b infectionviread 163 mg film coated tablets are indicated for the treatment of chronic hepatitis b in paediatric patients aged 6 to < 12 years who weigh from 22 kg to less than 28 kg, with:compensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum alt levels, or histological evidence of moderate to severe inflammation and/or fibrosis.  with respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.hiv 1 infectionviread 204 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of hiv 1 infected paediatric patients, with nrti resistance or toxicities precluding the use of first line agents, aged 6 to < 12 years who weigh from 28 kg to less than 35 kg.the choice of viread to treat antiretroviral experienced patients with hiv 1 infection should be based on individual viral resistance testing and/or treatment history of patients.hepatitis b infectionviread 204 mg film coated tablets are indicated for the treatment of chronic hepatitis b in paediatric patients aged 6 to < 12 years who weigh from 28 kg to less than 35 kg, with:compensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum alt levels or histological evidence of moderate to severe inflammation and/or fibrosis.  with respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.hiv 1 infectionviread 245 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of hiv 1 infected adults.in adults, the demonstration of the benefit of viread in hiv 1 infection is based on results of one study in treatment naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which viread was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).viread 245 mg film coated tablets are also indicated for the treatment of hiv 1 infected adolescents, with nrti resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.the choice of viread to treat antiretroviral experienced patients with hiv 1 infection should be based on individual viral resistance testing and/or treatment history of patients.hepatitis b infectionviread 245 mg film coated tablets are indicated for the treatment of chronic hepatitis b in adults with:compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1).evidence of lamivudine resistant hepatitis b virus (see sections 4.8 and 5.1).decompensated liver disease (see sections 4.4, 4.8 and 5.1).viread 245 mg film coated tablets are indicated for the treatment of chronic hepatitis b in adolescents 12 to < 18 years of age with:compensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum alt levels, or histological evidence of moderate to severe inflammation and/or fibrosis.  with respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.hiv 1 infectionviread 33 mg/g granules are indicated in combination with other antiretroviral medicinal products for the treatment of hiv 1 infected paediatric patients, with nrti resistance or toxicities precluding the use of first line agents, from 2 to < 6 years of age, and above 6 years of age for whom a solid dosage form is not appropriate.viread 33 mg/g granules are also indicated in combination with other antiretroviral medicinal products for the treatment of hiv 1 infected adults for whom a solid dosage form is not appropriate.in adults, the demonstration of the benefit of viread in hiv 1 infection is based on results of one study in treatment naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which viread was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).the choice of viread to treat antiretroviral experienced patients with hiv 1 infection should be based on individual viral resistance testing and/or treatment history of patients.hepatitis b infectionviread 33 mg/g granules are indicated for the treatment of chronic hepatitis b in adults for whom a solid dosage form is not appropriate with:compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1).evidence of lamivudine resistant hepatitis b virus (see sections 4.8 and 5.1).decompensated liver disease (see sections 4.4, 4.8 and 5.1).viread 33 mg/g granules are also indicated for the treatment of chronic hepatitis b in paediatric patients2 to < 18 years of age for whom a solid dosage form is not appropriate with:compensated liver disease and evidence of immune active disease, i.e. active viral replication, and persistently elevated serum alt levels, or histological evidence of moderate to severe inflammation and/or fibrosis.  with respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

titan ag pty ltd - phosphine (ph3) present as aluminium phosphide - tablet (inc. pellet, bolus, suppository, capsule) - phosphine (ph3) present as aluminium phosphide gas active 330.0 g/kg - mixed function pesticide - grain storage area and/or facility | rabbit burrow | stored barley seed | stored breakfast cereal | stored bulk stock feed | sto - angoumois grain moth | bean weevil | cadelle | cigarette beetle | cockroach | coffee bean weevil | confused flour beetle | dried fruit beetle | flat grain beetle | granary weevil | hide or skin beetle | indian meal moth | lesser grain borer | maize weevil | mediterranean flour moth | merchant grain beetle | mottled grain moth | mouse - mus spp. | psocids or booklouse | rabbit | raisin moth | rat | redlegged ham beetle | rice weevil | rust-red flour beetle | sawtoothed grain beetle | spider beetle | stored product mite | tobacco moth | tropical warehouse moth | warehouse beetle | dermestes ater | dermestes maculatus | grain borer | large cockroach | small cockroach | tobacco beetle

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

titan ag pty ltd - chlorpyrifos; liquid hydrocarbon - emulsifiable concentrate - chlorpyrifos organophosphorus active 500.0 g/l; liquid hydrocarbon solvent other 473.0 g/l - insecticide - annual pasture-improved | apple | avocado | banana | barley | broad bean | cabbage | canola | carrot | cassava | cauliflower | c - african black beetle | ant | argentine ant | argentine stem weevil | australian plague locust | avocado leafroller | banana scab moth | banana weevil borer | black beetle | blackheaded pasture cockchafer | blue oat or pea mite | bluegreen aphid | brown pasture looper | brown planthopper | cabbage aphid | cabbage cluster caterpillar | cabbage moth | cabbage white butterfly | california red scale | caterpillar | cluster caterpillar | cockroach | cockroach infestation - heavy/residual | cockroach infestation - light | common armyworm | common armyworm - mythimna convecta | common mango scale | corn aphid | corn earworm | cotton aphid | cotton flea beetle | cricket | cutworm | cutworm - agrotis spp. | european earwig | false wireworm | false wireworm - celibe spp. | field cricket | flea | funnel ant | grapevine moth | grapevine scale | green peach aphid | green vegetable bug | hairy caterpillar | hide or skin beetle | ivy leafroller | latania scale | lawn armyworm | light brown apple moth | lucerne flea | lucerne

European Union - English - EMA (European Medicines Agency)

schering-plough europe - interferon alfa-2b - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b: treatment of adult patients with chronic hepatitis b associated with evidence of hepatitis b viral replication (presence of hbv-dna and hbeag), elevated alanine aminotransferase (alt) and histologically proven active liver inflammation and/or fibrosis.chronic hepatitis c:adult patients:introna is indicated for the treatment of adult patients with chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv (see section 4.4).the best way to use introna in this indication is in combination with ribavirin.chidren and adolescents:introna is intended for use, in a combination regimen with ribavirin, for the treatment of children and adolescents 3 years of age and older, who have chronic hepatitis c, not previously treated, without liver decompensation, and who are positive for serum hcv-rna. the decision to treat should be made on a case by case basis, taking into account any evidence of disease progression such as hepatic inflammation and fibrosis, as well as prognostic factors for response, hcv genotype and viral load. the expected benefit of treatment should be weighed against the safety findings observed for paediatric subjects in the clinical trials (see sections 4.4, 4.8 and 5.1).

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 270 µg/ml; ribavirin 200mg;  ;   - combination - 135µg/0.5ml + 200mg - active: peginterferon alfa-2a 270 µg/ml excipient: benzyl alcohol glacial acetic acid polysorbate 80 sodium acetate trihydrate sodium chloride water for injection active: ribavirin 200mg     excipient: ethylcellulose hypromellose as a component of opadry 03a14309 iron oxide red as a component of opadry 03a14309 iron oxide yellow as a component of opadry 03a14309 magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc as a component of opadry 03a14309 sodium starch glycolate titanium dioxide as a component of opadry 03a14309 triacetin - pegasys rbv is indicated for the treatment of chronic hepatitis c (chc) in: · non-cirrhotic patients · cirrhotic patients with compensated liver disease

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 360 µg/ml; ribavirin 200mg;  ;   - combination - 180µg/0.5ml + 200mg - active: peginterferon alfa-2a 360 µg/ml excipient: benzyl alcohol glacial acetic acid polysorbate 80 sodium acetate trihydrate sodium chloride water for injection active: ribavirin 200mg     excipient: ethylcellulose hypromellose as a component of opadry 03a14309 iron oxide red as a component of opadry 03a14309 iron oxide yellow as a component of opadry 03a14309 magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc as a component of opadry 03a14309 sodium starch glycolate titanium dioxide as a component of opadry 03a14309 triacetin - pegasys rbv is indicated for the treatment of chronic hepatitis c (chc) in: · non-cirrhotic patients · cirrhotic patients with compensated liver disease